Summary

Cancer Diagnostics Market Trends & Summary

Cancer Diagnostics market is expected to reach US$ 345.57 billion by 2033 from US$ 184.37 billion in 2024, with a CAGR of 7.23% from 2025 to 2033. Some of the key drivers driving the market include increased awareness of early disease diagnosis, the rising incidence of cancer as a result of genetic predisposition and lifestyle changes, and improvements in diagnostic procedures to improve patient care.

The report Cancer Diagnostics Market & Forecast covers by Application (Breast, Colorectal, Cervical, Lung, Prostate, Skin, Blood, Kidney, Liver, Pancreatic, Ovarian), Test Type (Tumor Biomarkers, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization), End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes, Others), Country and Company 2025-2033.


Cancer Diagnostics Industry Overview

Disease diagnostics is the most popular method of identifying various biomarkers, side effects, and proteins in patients that indicate the presence of dangerous growth. The identification of specific proteins and biomarkers that are routinely seen in tumors is the first step in the discoveries. Consequently, the identification of diseases depends on the use of accurate analytical tools and techniques.

Globally, cancer has a significant influence on society. With a greater prevalence in developed and emerging business sectors, it is one of the leading causes of death globally. Medical service providers are being forced to reconsider disease therapy goals and refocus their attention on anticipating due to the startling rate of increasing malignant development pervasiveness. Therefore, it would be necessary to have illness diagnostics that are touchy, explicit, and appropriate for identifying malignant development in its early stages.

The increasing global incidence of cancer is one of the primary factors propelling industry growth throughout the anticipated period. Furthermore, new developments in diagnostic testing are expected to spur future business expansion. Similarly, the expansion of the cancer diagnostics market is supported during the projection period by consistent government initiatives and growing awareness. The Biden-Harris organization, for instance, has set a goal to reduce the death rate from malignant growth by half over the next 25 years and to broaden our understanding of people who have and recover from cancer.

One of the main factors driving market expansion is the rise in cancer prevalence worldwide. The Pan American Health Organization (PAHO), for example, projects that by 2040, there will be over 30 million reported cases annually, with an estimated 20 million new cases and 10 million deaths anticipated in 2023. The market is expected to expand as a result of the need for diagnostics solutions that can identify diseases early, enhance illness management, and lower mortality. Additionally, one in five men and one in six women are predicted to get cancer at some point in their lives.


Growth Drivers for the Cancer Diagnostics Market

Improvements in diagnostic methods

In order to provide increased sensitivity, specificity, and accessibility, manufacturers are constantly improving their diagnostic technology. Accordingly, certain biomarkers linked to certain cancer types can be found using molecular and genetic testing methods including liquid biopsies and next-generation sequencing. These technologies enable tailored treatment strategies and offer insights into tumor features. In addition, advancements in imaging modalities like magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) provide more precise and detailed visualization of tumors, which helps in diagnosis and staging. Additionally, the accuracy of cancer diagnostics is improved by ongoing technological advancements, which is providing a favorable market outlook. The market overview for cancer diagnostics captures a vibrant and quickly changing sector characterized by advances in technology and rising need for individualized treatment plans and early detection.


Increasing knowledge of early disease detection

The market is expanding as a result of growing consumer awareness of the value of early cancer detection. People are looking for routine diagnostic testing and screenings to keep an eye on their health. In order to encourage proactive health-seeking behavior, healthcare organizations and clinicians are also putting together a number of campaigns to inform the public about the advantages of early intervention. In addition, early identification lowers the overall healthcare burden related to advanced-stage cancer while also improving treatment outcomes. Many nations' governing bodies and medical facilities are offering easily accessible screening programs and stressing the need of early cancer detection. These programs encourage people to get screened for cancer on a regular basis, which is helping the market. The market for cancer diagnostics is expanding due to factors like rising cancer prevalence, advances in diagnostic technology, and the increasing need for early detection and individualized treatment plans.


An increase in the incidence of cancer

Numerous variables, including aging populations, environmental exposures, changes in lifestyle, and genetic predispositions, contribute to the increased prevalence of cancer. Longer exposure times to possible carcinogens and cumulative genetic alterations are causing an increase in the number of cancer cases. Changes in lifestyle, such as eating poorly and not exercising, are also raising the risk of cancer. Aside from this, early detection is becoming more and more preferred by individuals in order to effectively treat cancer. The market is expanding as a result of people's increasing need for prompt and precise cancer diagnoses in order to prevent more consequences. In addition, the market's expansion is being supported by the growing accessibility of healthcare services.


Challenges in the Cancer Diagnostics Market

High Cost of Advanced Diagnostic Technologies

One major obstacle to the broad use of sophisticated cancer diagnostic tools is their high cost. Modern instruments like genetic testing, molecular diagnostics, and sophisticated imaging methods can be unaffordable, especially in environments with limited resources, which restricts access to early detection and individualized care. Even with cutting-edge technologies, the expense of individual tests exacerbates this problem by frequently making them unaffordable for many patients, particularly those without full insurance coverage. This financial strain impairs healthcare systems' capacity to provide prompt and precise diagnoses, which influences results and delays interventions. In order to provide fair access to cutting-edge cancer diagnostics, there is a rising demand for more reasonably priced diagnostic options as well as better insurance coverage.


Complexity in Diagnosing Certain Cancer Types

Certain cancer types, such brain, ovarian, or pancreatic cancer, are extremely difficult to diagnose since there are no trustworthy biomarkers or early signs, which makes early diagnosis difficult. Treatment choices and survival rates are decreased since these malignancies are sometimes not detected until they have progressed to an advanced stage. Diagnostics are further complicated by tumor heterogeneity, which refers to the genetic and genomic diversity of malignancies. Diagnostic tests that are successful for one subtype of cancer may not be effective for others because tumors can differ greatly in their genetic composition, even within a single cancer type. In order to improve the precision and efficacy of early diagnosis and treatment, this diversity makes it difficult to create standardized screening procedures and emphasizes the need for individualized diagnostic approaches catered to the genetic profile of specific cancers.


Diagnosis of lung cancer is a significant area of focus in the cancer diagnostics market

Lung cancer stands as a prominent focus in the cancer diagnostics market because of its excessive occurrence and mortality rates globally. According to the American Cancer Society, in 2023, an anticipated 238,340 people (117,550 guys and 120,790 women) may be recognized with lung cancer, and 127,070 human beings will die from the sickness. Early detection through advanced diagnostic gear is essential for improving the consequences of the affected person, making lung cancer analysis a substantial area of study and funding within the healthcare industry.


Cancer Diagnostics Market Overview by Regions

By countries, the global Cancer Diagnostics market is divided into United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, and New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, United Arab Emirates, and South Africa.


United States Cancer Diagnostics Market

The market for cancer diagnostics in the United States is expanding quickly because to rising cancer incidence, technological breakthroughs, and increased awareness of the value of early detection. The utilization of molecular diagnostics, genetic testing, liquid biopsy, and sophisticated imaging, which enable more precise and individualized diagnoses, is what defines the market. The need for precision medicine, better screening techniques, and advancements in non-invasive diagnostic technology are important motivators. But problems like exorbitant prices, problems with insurance coverage, and regulatory barriers still exist. The need for improved access to state-of-the-art diagnostics, especially in underprivileged groups, has an effect on the market as well. The market for cancer diagnostics in the United States is anticipated to grow further with continued research and innovation, providing new chances for earlier detection and improved treatment results.

The United States is expected to have 1,958,310 new cases of cancer by 2023, up from 1,918,030 in 2022, according to the American Cancer Society's (ACS) statistics. In addition, breast cancer is predicted to be the most common cancer in women, with an estimated 300,590 new cases expected in 2023 compared to 290,560 in 2022. In a similar vein, colon cancer cases are predicted to rise from 80,690 in 2022 to 81,860 in 2023. More screening tests are required in order to lessen the burden of colorectal cancer due to its high prevalence. This propels the market under study's expansion.


United Kingdom Cancer Diagnostics Market

The market for cancer diagnostics in the United Kingdom is growing due to factors such increased emphasis on early detection, improvements in diagnostic technologies, and rising cancer incidence. Innovations in imaging, liquid biopsies, and molecular diagnostics that enable more accurate, non-invasive, and customized diagnosis are important motivators. The market is expanding as a result of the NHS's investment in screening initiatives and the expanding use of genetic testing. Long wait periods for testing, restricted availability in rural regions, and the expensive cost of modern diagnostics are still problems, though. In order to approve innovative technology and guarantee their incorporation into clinical practice, the market must also overcome regulatory obstacles. The UK cancer diagnostics market is anticipated to continue developing with continued research and technology improvements as the need for precision treatment and early detection increases.


China Cancer Diagnostics Market

The market for cancer diagnostics in China is expanding quickly due to factors such increased cancer incidence, rising healthcare spending, and improvements in diagnostic technology. The use of genetic testing, molecular diagnostics, and sophisticated imaging technologies that enhance early detection and individualized therapy is propelling the industry. The market is growing as a result of government attempts to increase access to healthcare, including as investing in rural healthcare facilities and extending screening programs. There are still issues, though, such as the high expense of sophisticated tests, rural communities' restricted access to state-of-the-art equipment, and regional variations in healthcare quality. Notwithstanding these obstacles, the market is expanding due to the need for earlier, more precise cancer detection, and China is fast emerging as a center for cancer diagnostics innovation.

China's massive population and rising cancer rates are expected to fuel the country's potential development in the global cancer diagnostics market. In 2022, China recorded 2,574,200 cancer-related deaths and 4,824,700 new cases, with lung, colon-rectum, thyroid, liver, and stomach cancers accounting for 57.42% of cases, according to a Science Direct article. China wants to strengthen its position by emphasizing advanced diagnostics and healthcare facilities. In order to address the enormous demand for cancer detection and treatment, initiatives such as ""Healthy China 2030"" aim to raise cancer survival rates by 15% by 2030 and offer comprehensive chronic illness care.


Saudi Arabia Cancer Diagnostics Market

The market for cancer diagnostics in Saudi Arabia is growing as a result of improvements in diagnostic technology, increased healthcare awareness, and an increase in cancer prevalence. The market is distinguished by the growing use of advanced imaging methods, genetic testing, and molecular diagnostics, which improve early detection and individualized care. The goal of government programs like the Saudi Vision 2030 healthcare reforms is to expand access to cutting-edge technologies and enhance diagnostic infrastructure. However, issues including dependence on imported technologies, restricted availability in remote areas, and the high cost of modern diagnostics continue to exist. The market is expanding due to the need for early-stage detection and the growing emphasis on precision medicine. It is anticipated that Saudi Arabia's cancer diagnostics market would continue to develop, enhancing patient outcomes and treatment effectiveness, with ongoing healthcare investments and innovation.


Application – Market breakup in 12 viewpoints:
1. Breast Cancer
2. Colorectal Cancer
3. Cervical Cancer
4. Lung Cancer
5. Prostate Cancer
6. Skin Cancer
7. Blood Cancer
8. Kidney Cancer
9. Liver Cancer
10. Pancreatic Cancer
11. Ovarian Cancer
12. Others


Test Type – Market breakup in 6 viewpoints:
1. Tumor Biomarkers Tests
2. Imaging
3. Biopsy
4. Liquid Biopsy
5. Immunohistochemistry
6. In Situ Hybridization


End-User – Market breakup in 4 viewpoints:
1. Diagnostic Centers
2. Hospitals and Clinics
3. Research Institutes
4. Others


Country – Market of 25 Countries:
1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa


All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis


Company Analysis:
1. llumina
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc.
4. QIAGEN N.V.
5. Roche Holding AG.
6. Pfizer, Inc.
7. Koninklijke Philips N.V.
8. bioMérieux


Key Questions Answered in Report:
1. How big is the Cancer Diagnostics industry?
The global Cancer Diagnostics market size was valued at US$ 184.37 billion in 2024 and is expected to reach US$ 345.57 billion in 2033.

2. What is the Cancer Diagnostics growth rate?
The global Cancer Diagnostics market is expected to expand at a compound annual growth rate (CAGR) of 7.23% from 2025 to 2033.

3. Who are the key players in Cancer Diagnostics industry?
Some key players operating in the Cancer Diagnostics market includes Illumina, Abbott Laboratories, Thermo Fisher Scientific, Inc., QIAGEN N.V., Roche Holding AG, Pfizer, Inc., Koninklijke Philips N.V., and bioMérieux.

4. What are the factors driving the Cancer Diagnostics industry?
Advances in molecular diagnostics, early detection technologies, rising cancer prevalence, greater healthcare spending, more awareness, better screening techniques, individualized therapy, and the need for more precise and non-invasive testing are the main drivers of the cancer diagnostics market.

5. Which Region held the largest market share in the Cancer Diagnostics industry?
North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Cancer Diagnostics Market report?
Application, Test Type, End User and Countries segment are covered in this report.

ページTOPに戻る

Table of Contents

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Global Cancer Diagnostics Market


6. Market Share
6.1 By Application
6.2 By Test Type
6.3 By EndUsers
6.4 By Country


7. Application
7.1 Breast Cancer
7.2 Colorectal Cancer
7.3 Cervical Cancer
7.4 Lung Cancer
7.5 Prostate Cancer
7.6 Skin Cancer
7.7 Blood Cancer
7.8 Kidney Cancer
7.9 Liver Cancer
7.10 Pancreatic Cancer
7.11 Ovarian Cancer
7.12 Others


8. Test Type
8.1 Tumor Biomarkers Tests
8.2 Imaging
8.3 Biopsy
8.4 Liquid Biopsy
8.5 Immunohistochemistry
8.6 In Situ Hybridization


9. End-User
9.1 Diagnostic Centers
9.2 Hospitals and Clinics
9.3 Research Institutes
9.4 Others


10. Country
10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa


11. Porter’s Five Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Company Analysis
13.1 llumina

13.1.1 Overviews
13.1.2 Recent Developments
13.1.3 Revenues

13.2 Abbott Laboratories

13.2.1 Overviews
13.2.2 Recent Developments
13.2.3 Revenues

13.3 Thermo Fisher Scientific, Inc

13.3.1 Overviews
13.3.2 Recent Developments
13.3.3 Revenues

13.4 QIAGEN N.V.

13.4.1 Overviews
13.4.2 Recent Developments
13.4.3 Revenues

13.5 Roche Holding AG.

13.5.1 Overviews
13.5.2 Recent Developments
13.5.3 Revenues

13.6 Pfizer, Inc.

13.6.1 Overview
13.6.2 Recent Development
13.6.3 Financial Insights

13.7 Koninklijke Philips N.V.

13.7.1 Overview
13.7.2 Recent Development
13.7.3 Financial Insights

13.8 bioMérieux

13.8.1 Overview
13.8.2 Recent Development
13.8.3 Financial Insights